期刊文献+

利伐沙班和低分子肝素钠预防膝关节交叉韧带重建术后深静脉血栓形成疗效比较 被引量:4

Comparative of effects between rivaroxaban and low molecular weight heparin sodium on preventing deep vein thrombosis in patients with reconstruction of cruciate ligament of knee joint
下载PDF
导出
摘要 (1)目的比较利伐沙班、低分子肝素钠预防膝关节交叉韧带重建术后深静脉血栓(Deep Vein Thrombosis,DVT)形成的疗效和安全性。(2)方法选取2014年7月~2016年8月收治的80例行手术治疗的膝关节交叉韧带损伤患者为研究对象,其中男49例,女31例;年龄19~62岁,平均(34.8±10.2)岁。按照随机原则分为利伐沙班组和低分子肝素钠组,各40例。两种药物均按照用药规范进行抗凝治疗。于术前及术后两周行下肢彩色多普勒超声检查,观察深静脉血栓及其他出血事件发生情况,并检测术前、术后活化部分凝血活酶时间(Activated Partial Thromboplastin Time,APTT)、凝血酶原时间(Prothrombin Time,PT)、血小板(Platelet,PLT)等各项指标。(3)结果利伐沙班组DVT发生率为2.5%(1/40),低分子肝素钠组为17.5%(7/40),两组间比较差异有统计学意义(χ2=5.000,P<0.05);两组患者术后APTT、PT、PLT差异均无统计学意义(P>0.05)。(4)结论利伐沙班对于预防膝关节交叉韧带重建术后下肢DVT的有效性和安全性优于低分子肝素钠。 Objective To compare the efficacy and safety of rivaroxaban and low molecular weight heparin sodium(LMWHS) for deep vein thrombosis(DVT)in patients with reconstruction of cruciate ligament of knee joint.Methods A total of 80 patients with cruciate ligament injured of knee joint hospitalized and treated by operation from July 2014 to August 2016 were selected as research subjects,among whom 49 males and 31 females with a mean age of(34.8±10.2)years old(19±62 years).All patients were randomly divided into two groups,40 in each group.Two drugs were given to patients according to the present guidelines.Color Doppler ultrasound was used to identify DVT before operation and after two weeks, the occurrence of other bleeding events were also recorded. Activated partial thromboplastin time(APTT).prothrombin time(PT).platelet(PLT)were tested respectively on preoperation and after surgery. Results DVT incidence in rivaroxaban group(2.5 %, 1/40)was lower than that in LMWHS group ( 17.5 ±, 7/40) with significant difference (Х^2 = 5. 000, P 〈 0.05). The two drugs also showed no significant difference in APTT, PT and PLT after surgy(P〉0.05). Conclusion Rivaroxaban can reduce the incidence of DVT without increasing bleeding in patients with reconstruction of cruciate ligament of knee joint.
出处 《华北理工大学学报(医学版)》 2017年第2期123-126,共4页 Journal of North China University of Science and Technology:Health Sciences Edition
关键词 深静脉血栓 利伐沙班 低分子肝素钠 交叉韧带 重建 Deep vein thrombosis.Rivaroxaban.Low molecular weight heparin sodium.Cruciate ligament. Reconstruction
  • 相关文献

参考文献3

二级参考文献28

  • 1闫钧,郑起,汪昱,陆洪芬,薛琼,汤钊猷.达肝素钠对肝癌生长转移抑制的实验研究[J].中华肝脏病杂志,2005,13(5):359-361. 被引量:4
  • 2林平,林英,王晓红.低分子肝素[J].临床军医杂志,2006,34(5):630-632. 被引量:26
  • 3林建华,张建平,贺晶,黄引平,余艳红.低分子肝素在产科中的应用[J].现代妇产科进展,2007,16(6):401-409. 被引量:64
  • 4Huisman MV, Ouinlan DJ, Dahl OE, et al. Enoxaparin versus dabig-atran or rivaroxaban for thromboprophylax- is after hip or knee arthro-plasty: results of separate pooled analyses of phase Ⅲ multicenterrandomized trials [J]. Circ Cardiovasc Qual Outcomes, 2010, 3 (6) : 652- 660.
  • 5Linhardt RJ,Loganathan D,al- Hakim A ,et al. Oligosac- charide mapping of low molecular weight heparins:strue- ture and activity differenees [ J ]. J Med Chem, 1990.33 (6) :1639 - 1645.
  • 6Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low - molecular - weight heparin: mechanisms of ac- tion, pharmacokineties, closing, monitoring, efficacy, and safety [ J ]. Chest,2001,119 ( 1 Suppl ) :64S - 94S.
  • 7Weitz Jl. Low - molecular - weight heparins[ J ]. N Engl J Med, 1997,337(10) :688 -698.
  • 8Zhang Q, Chen X,Zhu Z, et al. Struclural analysis of low molecular weight heparin by ultraperformance size exclu- sion chromatography/time of flight mass spectrometry and capillary zone electrophoresis [ J ]. Anel Chem, 2013,85 (3) :1819 - 1827.
  • 9Mann KG. Biochemistry and physiology of blood coagulation [J]. Thromb Haemost,1999,82:165 -74.
  • 10Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low - molecular - weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety [J]. Chest,2001,119(1 Suppl) :64S -94S.

共引文献51

同被引文献30

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部